STOCK TITAN

CANNAPHARMARX INC - CPMD STOCK NEWS

Welcome to our dedicated page for CANNAPHARMARX news (Ticker: CPMD), a resource for investors and traders seeking the latest updates and insights on CANNAPHARMARX stock.

CannaPharmaRx, Inc. is a company based in Calgary, Canada, that specializes in acquiring and developing cannabis cultivation projects in Canada. The company focuses on becoming a leader in high-quality, low-cost cannabis production through the acquisition and enhancement of existing facilities. With a commitment to utilizing the latest technology in combined heat and power generation to ensure cost efficiency, CannapharmaRx is dedicated to operating high-quality facilities. They recently finalized a supply agreement with ICAN Green S.A. de C.V., a division of ICAN Investing Group LLC, to supply products for distribution in the Latin Americas, with a primary focus on Mexico and Panama. This strategic partnership marks a significant milestone for both companies and emphasizes CannapharmaRx's commitment to global expansion and quality products.

Rhea-AI Summary
CannaPharmaRx, Inc. (CPMD) finalized a supply agreement with ICAN Green S.A. de C.V., a division of ICAN Investing Group LLC, to supply cannabis products in Latin America, focusing on Mexico and Panama. ICAN is a key player in cannabis education and research, being the first company to import THC API legally into Mexico. The agreement entails CannapharmaRx supplying ICAN with cannabis products, ensuring minimum annual purchases. This partnership signifies a strategic move for international expansion and revenue diversification for both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
none
-
Rhea-AI Summary
CannaPharmaRx, Inc. (CPMD) secures IMC-GAP and GACP certifications for cannabis production, enabling sales in Israel. The certifications highlight the company's commitment to quality, safety, and environmental standards, facilitating international expansion and product delivery in Israel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary
CannaPharmaRx (CPMD) announces a strategic Supply Agreement with Cantek Holdings, a leading player in Israel's medical cannabis industry. The agreement entails supplying a minimum of 1,000 kgs of product annually to Cantek, tapping into Israel's growing consumer demand. This move positions CannaPharmaRx in key international cannabis markets, leveraging Cantek's strong presence in Israel's medical cannabis sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60%
Tags
none
Rhea-AI Summary
CannaPharmaRx (CPMD) aims for substantial growth in the booming global cannabis industry, targeting revenue milestones and strategic partnerships. The company plans to leverage its advanced facilities in Alberta to drive revenue and profitability, with a focus on international sales and high-margin products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
-
News
Rhea-AI Summary
CannaPharmaRx expands Board of Directors to five, adding Anthony Panek and Adam Mindle. Mark Branson steps down.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
CannaPharmaRx appoints new CEO, Dean Medwid, with extensive experience in scalable process engineering and brand development. Medwid aims to drive growth and target new revenue opportunities. He plans to accelerate the company's growth trajectory and expand its footprint.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
management
Rhea-AI Summary

CannaPharmaRx (OTC PINK:CPMD) has signed a Memorandum of Understanding (MOU) with Nasha Genetics to enhance its presence in the medical cannabis sector. Nasha, recognized for its cannabis strain genetics, will supply CPMD with genetics that can produce high-quality cannabis with at least 20% THC. Under the agreement, Nasha will manage costs related to the genetic supply, while CannaPharmaRx will handle cultivation within 10 days of receiving the genetics. The partnership allows for a 7.5-year term during which Nasha will order at least 400 KG of cannabis from CannaPharmaRx, which will seek necessary export licenses for markets beyond Israel. A definitive agreement is expected within 45 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CannaPharmaRx (CPMD) announced a 24-month Supply Agreement with Israeli firm Y.S.A Holdings. Under this deal, CannaPharmaRx will cultivate cannabis in Canada and supply a minimum of 400kg annually to YSA for sales in Israel and Morocco, with potential revenues ranging from $6 million to $15 million per year. Deliveries are expected to start in Q3, with purchase orders occurring up to four times a year. This agreement is part of CannaPharmaRx's strategy to build an international brand featuring up to 15 cannabis strains from its exclusive inventory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
Rhea-AI Summary

CannaPharmaRx (OTC PINK:CPMD) has signed a letter of intent to acquire LTB Management LLC, an e-commerce platform that enhances online sales. The deal is expected to close in February 2023. LTB's revenues were approximately $3 million in 2022 and are projected to exceed $5 million in 2023 as new products, including cannabis, are introduced. This acquisition is aimed at boosting CannaPharmaRx's sales in Israel and Europe and will diversify its revenue streams, targeting an annual cannabis sales run rate of nearly $30 million. The platform will also enable additional payment options including e-wallets and cryptocurrencies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
none

FAQ

What is the current stock price of CANNAPHARMARX (CPMD)?

The current stock price of CANNAPHARMARX (CPMD) is $0.009 as of December 23, 2024.

What is the market cap of CANNAPHARMARX (CPMD)?

The market cap of CANNAPHARMARX (CPMD) is approximately 5.3M.

Where is CannaPharmaRx, Inc. based?

The company is based in Calgary, Canada.

What is the core focus of CannapharmaRx?

CannapharmaRx focuses on acquiring and developing cannabis cultivation projects in Canada.

What recent partnership did CannapharmaRx finalize?

CannapharmaRx recently finalized a supply agreement with ICAN Green S.A. de C.V. for product distribution in the Latin Americas.

What is CannapharmaRx's business strategy?

The company's strategy is to become a leader in high-quality, low-cost cannabis production through the acquisition and enhancement of existing facilities.

What technology does CannapharmaRx use for cost efficiency?

CannapharmaRx utilizes the latest technology in combined heat and power generation for cost efficiency.

What milestone did the partnership with ICAN represent?

The partnership with ICAN marked a significant milestone in CannapharmaRx's strategic global expansion.

Who is the CEO of CannapharmaRx?

Dean Medwid is the CEO of CannapharmaRx.

What is the annual production capacity of CannapharmaRx's facility?

The annual production capacity is 6000kg or approximately $18 million in top line revenue.

What did CannapharmaRx recently announce regarding convertible notes?

CannapharmaRx recently announced the extinguishment of convertible notes to avoid potential stock dilution and protect shareholder interests.

What upcoming event did CannapharmaRx announce?

CannapharmaRx announced that it will hold an investor conference call on March 19, 2024, to provide an update on the year-to-date progress of the company.

CANNAPHARMARX INC

OTC:CPMD

CPMD Rankings

CPMD Stock Data

5.30M
661.88M
0.09%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Calgary